Antengene Corporation Limited (Antengene), a leading innovative commercial stage global biopharmaceutical company, announced that the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health has registered Xpovio (selinexor) for two indications: (1) In combination with bortezomib and dexamethasone (XBd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy and (2) in combination with dexamethasone (Xd) for the treatment of adult patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor (PI), at least one immunomodulatory medicinal product (IMiD), and an anti-CD38 monoclonal antibody (mAb).
Xpovio is the first and only SINE approved by the TGA that helps to restore the body
